Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema

Shahid Beheshti University of Medical Sciences

Status and phase: Unknown; Phase 3

Conditions: Diabetic Macular Edema

Treatments: Drug: bevacizumab; Drug: triamcinolone acetonide

Study type: Interventional

Funder types: Other

Identifiers

NCT00370669

8411

Details and patient eligibility

About

to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)

Full description

we entered 150 eyes into the study that recruitment of cases finished recently.Eligible eyes randomly assign to one of the study arms including intravitreal bevacizumzb, intravitreal bevacizumzb/triamcinolone and macular photocoagulation groups. Every patient needs at least 1 year followup. During this time BCVA, OCT, FA will be done for each patient and inaccording to interpretation of datas and fundus exam repeatation of injection will be done.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• case with clear media IOP below 23 mm/Hg female after menopause at least for 12 months or had 2 contraceptive roots visual acuity between 20/50 to 20/320

Exclusion criteria

• no PRP or N.d YAG laser in past 6 months no intraocular surgery in past 12 months
• CVA in past 12 months blood sugar above 250
• active infection in extraocular adnexa

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind